Global Markets End on a Mixed Note

Sat, 8 Jul RoundUp

   Previous Close   

Crude oil prices fell by 4.5% during the week. The correction took place post the US government data reflecting that the production of crude oil and rig counts had risen. This data comes at a time where the oil production of Organization of the Petroleum Exporting Countries (OPEC) have hit a 2017 high. The world economy is facing a situation of oil oversupply. An increase in production by the US, will not bode down well for the crude oil prices.

To keep a tab on the movements in crude oil and other commodities, you can read the stock market commentary from the Daily Profit Hunter team. Their commentary tracks the developments in the global economy as well as stock, currency and commodity markets.

Benchmark indices in the US ended the week marginally higher by 0.3%. Minutes from the Federal Reserve's last meeting released showed a lack of consensus on the future pace of US interest rate increases. Fed policymakers were increasingly split on the outlook for inflation and the economic growth in the US.

US Federal Reserve rate hikes generally have a negative impact on emerging economies. But India is currently seen as better equipped than other emerging markets to ride the impact of higher US interest rates. That's largely because of its stronger economic growth and impressive foreign exchange reserves of more than US$300 billion.

Only time will tell whether the Fed will increase their interest rates further or not. Meanwhile, we'll keep you posted on the latest developments on this front.

Apart from the Fed, the European Central Bank (ECB) also released the minutes of their latest meeting on Thursday. As per the minutes, ECB policymakers are open to a further step toward reducing their monetary stimulus. However, they are likely to move slowly on this decision out of fear of causing market turmoil. The stock markets in Germany and France gained by 0.5% and 0.5% respectively during the week.

Key World Markets During the Week

Back home, S&P BSE Sensex gained 1.4% during the week. Major sectoral indices ended the week on a positive note with realty sector rallying the most and gaining 5.5% during the week.

BSE Indices During the Week

Now let us discuss some key economic and industry developments during the week gone by

As per the global rating agency Moody's, the Goods and Services Tax (GST) regime will be positive for India's credit profile as it will contribute to productivity gains and higher GDP growth as well as support higher government revenue generation through improved tax compliance.

Moody's positive reaction on GST will come as a shot in the arm of government as there are concerns that the initial teething problem will impact economic growth in the short term.

Moody's has a 'Baa3' rating on India with a positive outlook. Meanwhile, industry body Confederation of Indian Industry (CII) said that going forward, GST will contribute to ease of doing business and accelerate new business ventures.

Rahul Shah-Managing Editor of Microcap Millionaires, too is of the view that GST will be a long term positive for the economy. In one of his recent articles he stated how the organized sector is set to benefit in a huge way from this reform. Click here to read this excellent piece.

Initial Public Offer (IPO) have caught the frenzy of investor. There are almost a couple of IPO's hitting the market every month. However, are IPO's a sure shot way to make money in the stock markets?

According to Hindu Business Line, till June 2016, only 40% of the IPOs launched between 2004 and 2011 were trading above their issue price, as can be seen from the chart below. So the best way to invest in IPOs is by evaluating each IPO on its merits by considering its fundamentals, and most importantly, the valuations. And this is particularly important when the hype surrounding IPOs is at its peak.

If you're new to the 'lovely' world of IPOs, we have something for you...

Our new and completely free report - How to Get Rich with IPOs - will tell you how to find those money spinning IPOs and avoid the disasters in the coming year and beyond.

The growth in India's manufacturing sector fell to a four-month low in June amidst a slowdown in new order and production ahead of the implementation of the goods & services tax (GST). The Nikkei India Manufacturing Purchasing Managers' Index (PMI) slipped to 50.9 in June from 51.6 in May. A reading above 50 implies an expansion, while one below 50 denotes a contraction.

PMI data highlighted a slowdown in growth across India's manufacturing sector during June. As per the survey report, challenging economic conditions, water shortages and the implementation of the GST reportedly hampered growth.

However, this is not surprising given the way businesses were struggling with the GST implementation. As the 1 July deadline approached, there were reports of destocking and supply-chain disruption in various sectors. Thus, an adverse impact on production cycles was largely expected.

On a brighter side, the PMI survey showed strong foreign demand for Indian-manufactured products in June. With the impact of demonetisation largely over, Pollyanna De Lima, Economist at IHS Markit and the author of the report, does not expect GST to derail consumer spending and has forecast real GDP growth at 7.3% for 2017-18.

Stocks in the pharmaceuticals sector are going through a rough patch. A downgrade in the earnings estimates has led to a sell-off in pharma stocks. And this, in turn, has led to a contraction in the price to earnings ratio (PE ratio) of pharma index.

One other reason for the above sell-off is increasing USFDA alerts on Indian pharma companies during the past few years. USFDA alerts on Indian pharma companies have increased over the past few years. Regulators used to visit the plants every two years. Now they come every eight months. Increasing inspections has led to a total of 41 import alerts in the past eight years - 33 of them (80%) in just the last four years (2013-16). This clearly signifies increased USFDA scrutiny on Indian pharma firms. If that wasn't enough, increasing pricing pressure in the generics segment has dented realizations.

However, the recent development of USFDA expediting the drug approval process can bring some respite for Indian pharma companies. This comes as drug approvals for Indian companies have gone up 50% in the period from January to June 2017. With the above developments, we believe, companies with strong R&D capabilities and compliant plants (subscription required) will do well over the long term.

In the latest issue of The India Letter (subscription required), we have identified a pharma stock which we believe will outlast others in the long run.

Movers and Shakers During the Week

Company	30-Jun-17	07-Jul-17	Change	52-wk High/Low
Top Gainers During the Week (BSE Group A)
Unitech	5.98	7.82	30.8%	9/4
Videocon Industries	20.8	26.35	26.7%	115/16
Jubiliant Foodworks	945.45	1094.2	15.7%	1,229/761
Gujarat Fluoro	738.8	836.35	13.2%	844/451
Ashok Leyland	93.85	104.25	11.1%	109/74
Top Losers During the Week (BSE Group A)
Tata Communication	722	667.95	-7.5%	784/430
Max Financial Services Ltd	627.55	593.6	-5.4%	683/477
IPCA Labs	491.2	467.85	-4.8%	656/437
Jaiprakash Power	5.56	5.3	-4.7%	7/4
Lanco Infratech	1.09	1.04	-4.6%	6/1

Source : Equitymaster

Some of the key corporate developments in the week gone by

Sun Pharmaceutical Industries has entered into a strategic long-term manufacturing agreement with Samsung Biologics for Tildrakizumab. The agreement was entered into by Sun Pharma's wholly-owned subsidiary and Samsung Biologics. According to the agreement, Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.

Filings for this novel investigational biologic has been accepted for review by the US Food and Drug Administration (USFDA) and the European Medicines Agency (EMA). As per the reports, the approximate value of the contract will be US$ 55.5 million.

As per an article in The Economic Times, Hero Motocorp has decided to put a complete halt on royalty payments to its former joint venture partner Honda. Since the termination of the Hero Honda joint venture in 2010, the company has forked out a total of Rs 3.88 billion to Honda in annual royalties. The two-wheeler giant will now tap its in-house R&D unit - the Centre of Innovation and Technology (CIT) in Jaipur, Rajasthan for all technology requirements.

Going forward, the company will have enhanced focus on the premium segment and scooters, with a slew of launches lined up over the next 8-12 months. The traction from domestic demand coupled with demand from its international operations will play a key role going forward.

Ashok Leyland reported its sales numbers for the month ended June 2017. The auto major registered sales growth of 11% on a year-on-year (YoY) basis to 12,330 units for the month of June 2017.

It had suffered a decline of 8% in total sales during May 2017 on the back of the downslide in medium and heavy commercial vehicles.

During June 2017, the growth is led by light commercial vehicles at 29% with sales of 3,128 units.

The total sales in the April-June 2017 period stood at 28,495 as compared to 31,165 units in the year-ago period, declining by 9%. Further, the company's M&HCV sales in June 2017 was also up by 6%.

Notably, the company has in recent years, expanded its network rapidly to cater to its wide range of customers. At the end of FY17, its network had expanded to 2,678 touch points with plans to grow it rapidly during FY18.

As per an article in a leading financial daily, Bharat Heavy Electrical (BHEL) has entered into a Technology Collaboration Agreement with Kawasaki Heavy Industries, Japan for the manufacture of stainless steel coaches and bogies for metros.

The agreement covers establishing state-of-the-art design, engineering and manufacturing facilities at BHEL.

The Agreement has been signed in the backdrop of our Prime Minister's "Make in India" initiative, and will enable BHEL to produce stainless steel coaches indigenously and help in bringing technology upgrades in its expanding portfolio.

For BHEL, the alliance is a key step in its efforts to diversify from its traditional business. It will also expand the company's business of supplying electric and diesel locomotives to the Indian Railways.

As markets hit historical highs, the benchmark index, S&P BSE Sensex, is trading at a price to earnings of 22.3 times. Valuations seem to be a bit stretched. Unless earnings pick up in the coming quarters, a correction to the index seems likely. In such times, it's important to be extremely disciplined about the businesses you buy. Compromising on quality could prove fatal.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Top Gainers TodayTop Gainers over 1-WeekTop Gainers over 1-MonthTop Gainers over 1-YearTop Gainers over 3-YrsTop Gainers over 5-YrsTop Losers TodayTop Losers over 1-WeekTop Losers over 1-MonthTop Losers over 1-YearTop Losers over 3-YrsTop Losers over 5-YrsOnly BuyersOnly SellersMost Active StocksMost Popular Stocks52 Week High Stocks52 Week Low Stocks

INDICESBSE (Rs 0 to 1)BSE (Rs 1 to 2)BSE (Rs 2 to 4)BSE (Rs 4 to 10)BSE (Rs 10 to 20)BSE (Above Rs 20)BSE - AllBSE-30BSE-100BSE-200BSE-500BSE AutoBSE BankexBSE Capital GoodsBSE Consumer DurablesBSE FMCGBSE HealthcareBSE ITBSE MetalBSE Oil & GasBSE PSUBSE TeckBSE RealtyBSE PowerBSE A GroupBSE B GroupBSE Mid-CapBSE Small-CapBSE Basic MaterialsBSE Consumer DiscretionaryBSE IndustrialsBSE UtilitiesBSE Sensex 50BSE Sensex Next 50BSE Bharat 22BSE 150 MidCapBSE 250 SmallCapBSE 250 LargeMidCapBSE 400 MidSmallCapBSE AllCapBSE LargeCapBSE SmallCap SelectBSE 100 LargeCap TMCBSE InfraBSE ManufacturingBSE CPSEBSE Private BankBSE Diversified FinancialsBSE MomentumBSE Low VolatilityBSE QualityBSE Enhanced ValueBSE Divident StabilityS&P BSE IPOBSE SMEIPOBSE 100 ESGBSE CarbonexBSE GreenexNSE (Rs 0 to 10)NSE (Rs 10 to 20)NSE (Above Rs 20)NSE - AllNSE-50NSE ITNSE Nifty Midcap 50NSE JR. NiftyNSE Bank NiftyNIFTY Next 50NIFTY 100NIFTY 200NIFTY 500NIFTY MidCap 100NIFTY SmallCap 250NIFTY SmallCap 50NIFTY SmallCap 100NIFTY LargeMidCap 250NIFTY MidSmallCap 400NIFTY AutoNIFTY Consumer DurablesNIFTY FinanceNIFTY FMCGNIFTY MediaNIFTY MetalNIFTY PharmaNIFTY Private BankNIFTY PSU BankNIFTY RealtyNIFTY Oil & GasNIFTY SME EmergeNIFTY CommoditiesNIFTY CPSENIFTY EnergyNIFTY India ConsumptionNIFTY InfraNIFTY MNCNIFTY PSENIFTY Serv SectorNIFTY100 Liquid 15NIFTY Midcap Liquid 15NIFTY Midcap 150 Quality 50NIFTY50 Equal WeightNIFTY100 Equal WeightNIFTY100 Low Volatility 30NIFTY100 Alpha 30NIFTY Alpha 50NIFTY Dividend Opportunities 50NIFTY High Beta 50NIFTY Low Volatility 50NIFTY200 Quality 30NIFTY 500 Value 50NIFTY 100 Quality 30SECTORSAgricultureAirlinesAluminiumAsset Management CompaniesAutomobilesAuto AncillariesBanks (Private)Banks (PSU)BankingCementChemicalsDefenceDiagnosticsDronesEngineeringElectric VehicleElectric Vehicle BatteryEnergy SourcesESGEthanolFertilizersFintechFMCGFoodGreen HydrogenHotelsInfrastructureInsuranceInvestment and FinanceInvITIT (Large)IT (Others)LogisticsMediaMetalMiningIndia's Big Tech StocksIndian PharmaMNC PharmaPSUPaintPaperPlasticPowerRating AgenciesReal EstateREITsRenewable EnergyRetailingSemiconductorShippingSteelSugarSupply ChainTelecomTextilesTravel Support Services

10 results 25 results 50 results 100 results All results

Indian Share Market Update: Top Gainers and Losers